Weekly News Amount
Financing ${lastRankDetail.financing_pages.length}
Product ${lastRankDetail.product_pages.length}
Negative ${lastRankDetail.sentiment_pages.length}
NiuFuSi is the first ophthalmic gene drug research and development company in China, located in Wuhan Optics Valley Bio-city, a national bio-industrial park. Committed to the research and drug development of gene therapy for ocular genetic diseases. NiuFuSi Company first chose leber hereditary optic neuropathy (LHON) as a breakthrough. Since 2008, it has carried out a lot of basic research. In 2011, it completed the world's first clinical study of gene therapy for patients with Leber hereditary optic neuropathy. Nine patients with Leber hereditary optic neuropathy who participated in the clinical study have been observed for seven years


Events ${currentEventsPage.count} Events
Events (${currentEventsPage.count}) Date
Nothing Happens :-(
${e.desp} ${e.date}
News ${ rankDetail.pages.length } News Articles ${currentTimeRange.start} ~ ${currentTimeRange.end}
Article (${rankDetail.pages.length}) Tag
${article.en_title} ${article.tag}
Industry Financing Info


Intelligence 0 Research Briefs


Competitors 0 Competitors